CNBC Stock Blog
- How Stock Investors Can Play Holiday Travel
- 3 Growth Opportunities in Tech: Analyst
- Prep Your Portfolio for Next Week: Stock Pickers
- Global Growth Good for Portfolio: Stock Picker
- Expect Tech Sector to Rise in Q4: Strategist
- Expect a 5-10% Market Pullback: Stock Picker
- 3 Stock Picks for This Volatile Environment: Portfolio Manager
- 3 Financial Stocks May Lead Final Rally: Market Researcher
- Gold's 'Money' Value is $4,000 to $11,000: Market Strategist
- Commercial Real Estate Bottom Near: Market Pro
MOST SHARED
- Wall Street Finds Profits by Reducing Mortgages
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- Kraft Weighs Higher Cadbury Bid as Rivals Circle
- MBS Buyback Program Should be Extended: Fed's Bullard
- China Wind Power Reportedly Seeking $2.2 Billion in IPO
- Volkswagen to Triple China Sales by 2018
- China Should Stop Property Stimulus Now: Central Bank
- S&P Stocks Trading at New 52-Week Highs
- Losey: Asset Allocation At Retirement
- Farrell: Obama Hectored, Ignored and Restricted?
- Don't Dwell on Investment Mistakes; Move on, Like Buffett
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- Wave of Debt Payments Facing US Government
- US Job Losses to Bottom out Next Quarter: NABE
- Obama Jobs Forum May Be More Political Than Practical
- Late Payments on Credit Cards Drop in Third Quarter
- Smallest US Businesses Borrowing Again: PayNet
- Little Sign of Inflation on the Horizon: IMF
- Kraft Weighs Higher Cadbury Bid as Rivals Circle
- MBS Program Should be Extended: Fed's Bullard
- Tyson Food Profit Beats Estimates
RSS FEED
Text Size 
CNBC News Associate
Dr. Mark Monane, senior biotech analyst at Needham & Co., named some biotech stocks that look attractive.
Recommendations:
Allos Therapeutics [ALTH
Loading...
()
]—The company has a positive last trial for treating T-cell lymphoma, bladder cancer and lung cancer. “People may be treated in the real world by the end of this year,” Monane told CNBC.
Medarex [MEDX
Loading...
()
]—The company is in its late stage programs in testing melanoma, a tough-to-treat cancer. They also have solid partnerships with Bristol-Myers [BMY
Loading...
()
], Merck [MRK
Loading...
()
] and Johnson & Johnson [JNJ
Loading...
()
].
Cubist Pharmaceuticals [CBST
Loading...
()
]
Vertex Pharmaceuticals [VRTX
Loading...
()
]—They are in their last phase in developing a treatment for Hepatitis C.
Disclosure:
No immediate information was available for Monane or his firm.
______________________________
______________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes